Paclitaxel and carboplatin for recurrent salivary gland malignancies

M. Airoldi, G. Fornari, F. Pedani, S. Marchionatti, P. Gabriele, G. Succo, C. Bumma

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation. Patients and Methods: Fourteen patients (10 males, 4 females; median age 55 years, range 20 -70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks). All patients had been previously treated with surgery+radiotherapy and 8 with a cisplatin combination. One patient had a local lesion, 7 loco-regional recurrence and metastases and 6 patients had metastases only. Results: Overall 65 courses were given (median 5; range 2-6). Responses were: PR in 2 patients (14%) lasting 5 and 12 months; 7 NC (50%) with a median duration of 8.5 months (5-12); and 5 PD (36%). The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3 - 17+). Conclusion: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.

Original languageEnglish
Pages (from-to)3781-3783
Number of pages3
JournalAnticancer Research
Volume20
Issue number5 C
Publication statusPublished - 2000

Fingerprint

Carboplatin
Paclitaxel
Salivary Glands
Neoplasms
Carcinoma
Neoplasm Metastasis
Mucoepidermoid Carcinoma
Adenoid Cystic Carcinoma
Survival
Cisplatin
Area Under Curve
Histology
Adenocarcinoma
Radiotherapy
Recurrence
Drug Therapy

Keywords

  • Carboplatin and adenoid cystic carcinoma
  • Chemotherapy
  • Paclitaxel
  • Salivary gland carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Airoldi, M., Fornari, G., Pedani, F., Marchionatti, S., Gabriele, P., Succo, G., & Bumma, C. (2000). Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Research, 20(5 C), 3781-3783.

Paclitaxel and carboplatin for recurrent salivary gland malignancies. / Airoldi, M.; Fornari, G.; Pedani, F.; Marchionatti, S.; Gabriele, P.; Succo, G.; Bumma, C.

In: Anticancer Research, Vol. 20, No. 5 C, 2000, p. 3781-3783.

Research output: Contribution to journalArticle

Airoldi, M, Fornari, G, Pedani, F, Marchionatti, S, Gabriele, P, Succo, G & Bumma, C 2000, 'Paclitaxel and carboplatin for recurrent salivary gland malignancies', Anticancer Research, vol. 20, no. 5 C, pp. 3781-3783.
Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Research. 2000;20(5 C):3781-3783.
Airoldi, M. ; Fornari, G. ; Pedani, F. ; Marchionatti, S. ; Gabriele, P. ; Succo, G. ; Bumma, C. / Paclitaxel and carboplatin for recurrent salivary gland malignancies. In: Anticancer Research. 2000 ; Vol. 20, No. 5 C. pp. 3781-3783.
@article{9e72d68482ba414da4e1bbcd0050f36c,
title = "Paclitaxel and carboplatin for recurrent salivary gland malignancies",
abstract = "Background: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation. Patients and Methods: Fourteen patients (10 males, 4 females; median age 55 years, range 20 -70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks). All patients had been previously treated with surgery+radiotherapy and 8 with a cisplatin combination. One patient had a local lesion, 7 loco-regional recurrence and metastases and 6 patients had metastases only. Results: Overall 65 courses were given (median 5; range 2-6). Responses were: PR in 2 patients (14{\%}) lasting 5 and 12 months; 7 NC (50{\%}) with a median duration of 8.5 months (5-12); and 5 PD (36{\%}). The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3 - 17+). Conclusion: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.",
keywords = "Carboplatin and adenoid cystic carcinoma, Chemotherapy, Paclitaxel, Salivary gland carcinoma",
author = "M. Airoldi and G. Fornari and F. Pedani and S. Marchionatti and P. Gabriele and G. Succo and C. Bumma",
year = "2000",
language = "English",
volume = "20",
pages = "3781--3783",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 C",

}

TY - JOUR

T1 - Paclitaxel and carboplatin for recurrent salivary gland malignancies

AU - Airoldi, M.

AU - Fornari, G.

AU - Pedani, F.

AU - Marchionatti, S.

AU - Gabriele, P.

AU - Succo, G.

AU - Bumma, C.

PY - 2000

Y1 - 2000

N2 - Background: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation. Patients and Methods: Fourteen patients (10 males, 4 females; median age 55 years, range 20 -70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks). All patients had been previously treated with surgery+radiotherapy and 8 with a cisplatin combination. One patient had a local lesion, 7 loco-regional recurrence and metastases and 6 patients had metastases only. Results: Overall 65 courses were given (median 5; range 2-6). Responses were: PR in 2 patients (14%) lasting 5 and 12 months; 7 NC (50%) with a median duration of 8.5 months (5-12); and 5 PD (36%). The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3 - 17+). Conclusion: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.

AB - Background: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation. Patients and Methods: Fourteen patients (10 males, 4 females; median age 55 years, range 20 -70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks). All patients had been previously treated with surgery+radiotherapy and 8 with a cisplatin combination. One patient had a local lesion, 7 loco-regional recurrence and metastases and 6 patients had metastases only. Results: Overall 65 courses were given (median 5; range 2-6). Responses were: PR in 2 patients (14%) lasting 5 and 12 months; 7 NC (50%) with a median duration of 8.5 months (5-12); and 5 PD (36%). The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3 - 17+). Conclusion: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.

KW - Carboplatin and adenoid cystic carcinoma

KW - Chemotherapy

KW - Paclitaxel

KW - Salivary gland carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034529209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034529209&partnerID=8YFLogxK

M3 - Article

C2 - 11268454

AN - SCOPUS:0034529209

VL - 20

SP - 3781

EP - 3783

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 C

ER -